Prospective Cohort of Patients Treated Using Neoadjuvant Modified FOLFIRINOX 6 Cycles for Potentially Resectable Pancreatic Duct Adenocarcinoma, Candidate for Participation in the PANACHE02 Clinical Trial
N/A
The aim of our study is to build up biological, radiological and tissue col...
Status
Not Yet Recruiting
Location
CHU de Rouen
Start Date
2025-09
Trial ID
NCT07034703
Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.
PHASE3
The main purpose of
* To observe the overall survival of patients with res...
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
PHASE1
To investigate the tolerability and safety of ONO-7913 and ONO-4538 used in...
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis
PHASE1
Metastatic Pancreatic Cancer Disease is one of the most aggressive and dead...
A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)
NA
Pancreatic cancer exhibits significant heterogeneity, which poses a major c...